Key result
Childhood cancer survivors exposed to high-risk therapies had significantly increased risks of endocrine abnormalities, including primary hypothyroidism (HR 6.6; 95% CI 5.6-7.8), compared to unexposed.
Why the study?
Do high-risk therapeutic exposures increase the risk of endocrine abnormalities in aging survivors of childhood cancer compared to unexposed survivors and siblings?
Population
14,290 5-year survivors from the Childhood Cancer Survivor Study, with a median age 6 years at diagnosis and…
Comparison
High-risk therapeutic exposures vs Survivors not exposed to high-risk therapies…
Design
Cohort
Follow-up
median age 32 years at last follow-up
Authors
Loading...
May support intensified endocrine surveillance in exposed survivors; extends prior cohort data but remains hypothesis-generating.
Cohort (n=14,290)
Do high-risk therapeutic exposures increase the risk of endocrine abnormalities in aging survivors of childhood cancer compared to unexposed survivors and siblings?
Hazard Ratio: 6.6 (95% CI 5.6–7.8)
Endocrinopathies in childhood cancer survivors increase substantially over time, particularly in those with high-risk therapeutic exposures, highlighting the need for lifelong subspecialty follow-up.
Mostoufi‐Moab et al. (2016) conducted a cohort in Childhood cancer (n=14,290). High-risk therapeutic exposures vs. Survivors not exposed to high-risk therapies and siblings was evaluated on Primary hypothyroidism (HR 6.6, 95% CI 5.6 to 7.8). Childhood cancer survivors exposed to high-risk therapies had significantly increased risks of endocrine abnormalities, including primary hypothyroidism (HR 6.6; 95% CI 5.6-7.8), compared to unexposed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: